+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Insulinoma Treatment Market 2019-2023 - Product Image

Global Insulinoma Treatment Market 2019-2023

  • ID: 4745548
  • Report
  • December 2018
  • Region: Global
  • 114 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
Advances in laparoscopic treatment and diagnostic techniques have a considerable impact on the global insulinoma treatment market. This high cost of treatment, however, is a major challenge to the treatment of insulinoma, thus reducing patient adherence. Many government and non- government organizations, including companies are focusing on providing funding and grants as well as clinical assistance of ten treatment of various neuroendocrine tumors. Such funding programs encourage more patients to avail the treatment, which, in turn, increase the patient base. Such programs help patients adhere to the treatment regimen, even it is a long- term procedure. Analysts have predicted that the insulinoma treatment market will register a CAGR of over 4% by 2023.

Market Overview

Advanced diagnostic techniques

Insulinoma is one of the key segments of the neuroendocrine tumors. Therefore, such advance in the field of diagnosis of neuroendocrine tumors will have a positive impact on the global insulinoma treatment market.

Shortage of patients volunteering of clinical trails

Numerous patients volunteer to participate in clinical trails, which has led to many innovations in disease prevention and treatment over the years. Without the willingness of the participating patients, many other people would have suffered with disease.

For the detailed list of factors that will drive and challenge the growth of the insulinoma treatment market during the 2019-2023, view this report.

Competitive Landscape

The global insulinoma treatment market is moderately concentrated, and as the market is in a growth phase, the competition is intense. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Surgery - Market size and forecast 2018-2023
  • Drugs - Market size and forecast 2018-2023
  • Other treatments - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Surgery - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Surgery - Year-over-year growth 2019-2023 (%)
Exhibit 22: Drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Drugs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Other treatments - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other treatments - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 02: Impact of drivers and challenges
Exhibit 04: Vendor landscape
Exhibit 05: Landscape disruption
Exhibit 06: Vendors covered
Exhibit 07: Vendor classification
Exhibit 08: Market positioning of vendors
Exhibit 09: Ipsen Pharma - Vendor overview
Exhibit 10: Ipsen Pharma - Business segments
Exhibit 11: Ipsen Pharma - Organizational developments
Exhibit 12: Ipsen Pharma - Geographic focus
Exhibit 13: Ipsen Pharma - Segment focus
Exhibit 14: Ipsen Pharma - Key offerings
Exhibit 15: Ipsen Pharma - Key customers
Exhibit 16: Johnson & Johnson - Vendor overview
Exhibit 17: Johnson & Johnson - Business segments
Exhibit 18: Johnson & Johnson - Organizational developments
Exhibit 19: Johnson & Johnson - Geographic focus
Exhibit 20: Johnson & Johnson - Segment focus
Exhibit 21: Johnson & Johnson - Key offerings
Exhibit 22: Johnson & Johnson - Key customers
Exhibit 23: Novartis - Vendor overview
Exhibit 24: Novartis - Business segments
Exhibit 25: Novartis - Organizational developments
Exhibit 26: Novartis - Geographic focus
Exhibit 27: Novartis - Segment focus
Exhibit 28: Novartis - Key offerings
Exhibit 29: Novartis - Key customers
Exhibit 30: Pfizer - Vendor overview
Exhibit 31: Pfizer - Business segments
Exhibit 32: Pfizer - Organizational developments
Exhibit 33: Pfizer - Geographic focus
Exhibit 34: Pfizer - Segment focus
Exhibit 35: Pfizer - Key offerings
Exhibit 36: Pfizer - Key customers
Exhibit 37: Teva Pharmaceutical Industries - Vendor overview
Exhibit 38: Teva Pharmaceutical Industries - Business segments
Exhibit 39: Teva Pharmaceutical Industries - Organizational developments
Exhibit 40: Teva Pharmaceutical Industries - Geographic focus
Exhibit 41: Teva Pharmaceutical Industries - Segment focus
Exhibit 42: Teva Pharmaceutical Industries - Key offerings
Exhibit 43: Teva Pharmaceutical Industries - Key customers
Exhibit 44: Validation techniques employed for market sizing
Exhibit 45: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
Global Insulinoma Treatment Market 2019-2023

The analyst recognizes the following companies as the key players in the global insulinoma treatment market: Ipsen Pharma, Johnson & Johnson, Novartis, Pfizer, Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing awareness of neuroendocrine tumors.”

According to the report, one of the major drivers for this market is the advances in laparoscopic treatment and diagnostic techniques have a considerable impact on the market.

Further, the report states that one of the major factors hindering the growth of this market is the poor results in drugs performance tests postpone marketing approvals, which hampers the growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
Adroll
adroll